Spyridon Papapetropoulos - Net Worth and Insider Trading
Spyridon Papapetropoulos Net Worth
The estimated net worth of Spyridon Papapetropoulos is at least $144,003 dollars as of 2024-12-28. Spyridon Papapetropoulos is the Director of Adamas Pharmaceuticals Inc and owns about 15,975 shares of Adamas Pharmaceuticals Inc (ADMS) stock worth over $131,315. Spyridon Papapetropoulos is the Chief Medical Officer of Vigil Neuroscience Inc and owns about 4,000 shares of Vigil Neuroscience Inc (VIGL) stock worth over $6,600. Spyridon Papapetropoulos is also the Director of Lipocine Inc and owns about 1,279 shares of Lipocine Inc (LPCN) stock worth over $6,088. Details can be seen in Spyridon Papapetropoulos's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Spyridon Papapetropoulos has not made any transactions after 2022-11-22 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Spyridon Papapetropoulos
Spyridon Papapetropoulos Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Spyridon Papapetropoulos owns 2 companies in total, including Lipocine Inc (LPCN) , and Vigil Neuroscience Inc (VIGL) .
Click here to see the complete history of Spyridon Papapetropoulos’s form 4 insider trades.
Insider Ownership Summary of Spyridon Papapetropoulos
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| LPCN | Lipocine Inc | 2022-11-22 | director |
| VIGL | Vigil Neuroscience Inc | 2022-11-18 | Chief Medical Officer |
Spyridon Papapetropoulos Latest Holdings Summary
Spyridon Papapetropoulos currently owns a total of 3 stocks. Among these stocks, Spyridon Papapetropoulos owns 15,975 shares of Adamas Pharmaceuticals Inc (ADMS) as of March 11, 2021, with a value of $131,315 and a weighting of 91.19%. Spyridon Papapetropoulos owns 4,000 shares of Vigil Neuroscience Inc (VIGL) as of November 18, 2022, with a value of $6,600 and a weighting of 4.58%. Spyridon Papapetropoulos also owns 1,279 shares of Lipocine Inc (LPCN) as of November 22, 2022, with a value of $6,088 and a weighting of 4.23%.
Latest Holdings of Spyridon Papapetropoulos
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ADMS | Adamas Pharmaceuticals Inc | 2021-03-11 | 15,975 | 8.22 | 131,315 |
| VIGL | Vigil Neuroscience Inc | 2022-11-18 | 4,000 | 1.65 | 6,600 |
| LPCN | Lipocine Inc | 2022-11-22 | 1,279 | 4.76 | 6,088 |
Holding Weightings of Spyridon Papapetropoulos
Spyridon Papapetropoulos Form 4 Trading Tracker
According to the SEC Form 4 filings, Spyridon Papapetropoulos has made a total of 1 transactions in Adamas Pharmaceuticals Inc (ADMS) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Adamas Pharmaceuticals Inc is the acquisition of 5,975 shares on March 11, 2021, which cost Spyridon Papapetropoulos around $30,234.
According to the SEC Form 4 filings, Spyridon Papapetropoulos has made a total of 2 transactions in Vigil Neuroscience Inc (VIGL) over the past 5 years, including 1 buys and 1 sells. The most-recent trade in Vigil Neuroscience Inc is the sale of 300 shares on November 18, 2022, which brought Spyridon Papapetropoulos around $4,200.
According to the SEC Form 4 filings, Spyridon Papapetropoulos has made a total of 1 transactions in Lipocine Inc (LPCN) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Lipocine Inc is the acquisition of 1,279 shares on November 22, 2022, which cost Spyridon Papapetropoulos around $10,217.
Insider Trading History of Spyridon Papapetropoulos
- 1
Spyridon Papapetropoulos Trading Performance
GuruFocus tracks the stock performance after each of Spyridon Papapetropoulos's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Spyridon Papapetropoulos is 31.13%. GuruFocus also compares Spyridon Papapetropoulos's trading performance to market benchmark return within the same time period. The performance of stocks bought by Spyridon Papapetropoulos within 3 months outperforms 2 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Spyridon Papapetropoulos's insider trading performs compared to the benchmark.
Performance of Spyridon Papapetropoulos
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -9.44 | | | | | |
| Relative Return to S&P 500(%) | -9 | | | | | |
Spyridon Papapetropoulos Ownership Network
Spyridon Papapetropoulos Owned Company Details
What does Lipocine Inc do?
Who are the key executives at Lipocine Inc?
Spyridon Papapetropoulos is the director of Lipocine Inc. Other key executives at Lipocine Inc include director & President and CEO Mahesh V. Patel , Chief Medical Officer George Nomikos , and Principal Accounting Officer Krista Fogarty .
Lipocine Inc (LPCN) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Lipocine Inc (LPCN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Lipocine Inc (LPCN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Lipocine Inc (LPCN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Lipocine Inc Insider Transactions
Spyridon Papapetropoulos Mailing Address
Above is the net worth, insider trading, and ownership report for Spyridon Papapetropoulos. You might contact Spyridon Papapetropoulos via mailing address: C/o Adamas Pharmaceuticals, Inc., 1900 Powell St., Suite 1000, Emeryville Ca 94608.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
